Lars Brandén
CEO
K
Kolibri
This startup develops a novel cell-culture platform designed to optimize biologics manufacturing, initially focusing on gene therapies. Their technology aims to improve the efficiency and scalability of producing complex biological therapeutics.
- Biotechnology
- Hardware
Updated 6 months ago
Funding
Raised to date
$2.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current cell-culture methods for manufacturing biologics, particularly gene therapies, often suffer from inefficiencies and scalability challenges, leading to high production costs and limited availability of these advanced therapeutics. Traditional transfection methods can also disrupt cell processes, negatively impacting yield and quality.
Solution
Kolibri provides an acoustic transfection unit designed to enhance the efficiency and scalability of viral vector production for gene therapies. Their technology utilizes acoustic waves to concentrate cells into smaller working volumes, improving cell productivity and cost-effectiveness. The controlled acoustic environment minimizes shear stress, ensuring cell viability and maximizing transfection efficiency. This approach allows for higher viral vector titers with less disruption to cell processes, ultimately leading to increased yields and reduced batch requirements.
Target Audience
The primary target audience includes biopharmaceutical companies and research institutions involved in the development and manufacturing of gene therapies and other biologics.
Features
- Acoustic cell manipulation for low-shear transfection within 15 minutes
- Cell-agnostic platform applicable to various cell types and therapy modalities
- Scaled-down design concentrating cells into 10x smaller working volumes
- Controlled acoustic waves for media circulation and minimal shear stress
- Seamless integration into existing biomanufacturing processes
- Increased viral vector titers and higher yields without increasing starting materials